{"disease":{"id":"her2-mutant-non-small-cell-lung-cancer","name":"her2 mutant non small cell lung cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05246514","title":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT01827267","title":"Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Puma Biotechnology, Inc.","has_results":true},{"nct_id":"NCT05411276","title":"A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2","phase":"","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Beijing Chest Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}